Pyxis Oncology, Inc. (PYXS) Financial Statements (2026 and earlier)

Company Profile

Business Address	321 HARRISON AVENUE BOSTON, MA 02118
State of Incorp.	DE
Fiscal Year End	December 31
Industry (SIC)	2834 - Pharmaceutical Preparations (benchmarking)
More info	Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

	12/31/2025 Q4	9/30/2025 Q3	6/30/2025 Q2	3/31/2025 Q1	12/31/2024 Q4	9/30/2024 Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:	66,900	76,300	88,900	105,400	126,900	144,800
Cash and cash equivalent	15,422	8,919	10,733	12,759	19,473	12,056
Short-term investments	51,435	67,337	78,211	92,673	107,458	132,762
Other undisclosed cash, cash equivalents, and short-term investments	43	44	(44)	(32)	(31)	(18)
Restricted cash and investments	1,472	1,472	1,472	1,472	1,472	1,472
Receivables			3,000
Prepaid expense	3,776	5,345	6,540	4,967	4,037	2,578
Other undisclosed current assets	(43)	(44)	44	32	31	18
Total current assets:	72,105	83,073	99,956	111,871	132,440	148,868
Noncurrent Assets
Operating lease, right-of-use asset	11,418	11,637	11,847	12,049	12,242
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization	7,997	8,460	8,924	9,403	9,899	10,396
Intangible asset, including goodwill, after accumulated amortization	(514)	2,434	2,488	2,544	2,600	23,619
Intangible asset, excluding goodwill, after accumulated amortization	(514)	2,434	2,488	2,544	2,600	23,619
Other undisclosed noncurrent assets	514					12,428
Total noncurrent assets:	19,415	22,531	23,259	23,996	24,741	46,443
TOTAL ASSETS:	91,520	105,604	123,215	135,867	157,181	195,311
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities	19,439	17,752	16,110	12,922	16,230	18,927
Accounts payable	10,885	9,756	9,412	2,846	4,859	4,870
Accrued liabilities	8,554	7,996	6,698	10,076	11,371	14,057
Other undisclosed current liabilities	1,692	1,630	1,568	1,508	1,450	1,393
Total current liabilities:	21,131	19,382	17,678	14,430	17,680	20,320
Noncurrent Liabilities
Long-term debt and lease obligation	23	43	62	80	100	117
Finance lease, liability	23	43	62	80	100	117
Liabilities, other than long-term debt	16,958	17,400	17,832	18,254	18,650	21,194
Deferred income tax liabilities						2,164
Operating lease, liability	16,958	17,400	17,832	18,254	18,650	19,030
Total noncurrent liabilities:	16,981	17,443	17,894	18,334	18,750	21,311
Total liabilities:	38,112	36,825	35,572	32,764	36,430	41,631
Equity
Equity, attributable to parent	53,408	68,779	87,643	103,103	120,751	153,680
Common stock	63	62	62	62	60	59
Additional paid in capital	496,469	493,719	490,654	487,706	484,077	481,255
Accumulated other comprehensive income (loss)	53	69	(5)	49	170	351
Accumulated deficit	(443,177)	(425,071)	(403,068)	(384,714)	(363,556)	(327,985)
Total equity:	53,408	68,779	87,643	103,103	120,751	153,680
TOTAL LIABILITIES AND EQUITY:	91,520	105,604	123,215	135,867	157,181	195,311

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

	12/31/2025 Q4	9/30/2025 Q3	6/30/2025 Q2	3/31/2025 Q1	12/31/2024 Q4	9/30/2024 Q3
Revenues	11,038	684	2,820	515		705
Sublease income	692	684	684	515	714	705
Other undisclosed gross profit	(2,388)
Gross profit:	8,650	684	2,820	515		705
Operating expenses	(26,945)	(23,461)	(22,570)	(22,914)	(40,069)	(23,754)
Other undisclosed operating loss		(684)		(515)		(705)
Operating loss:	(18,295)	(23,461)	(19,750)	(22,914)	(40,069)	(23,754)
Nonoperating income	1,292	1,458	1,679	1,756	2,334	2,551
Investment income, nonoperating	600	774	995	1,241	1,620	1,846
Loss from continuing operations before income taxes:	(17,003)	(22,003)	(18,071)	(21,158)	(37,735)	(21,203)
Income tax expense	(1,103)		(283)
Other undisclosed income from continuing operations					2,164
Net loss available to common stockholders, diluted:	(18,106)	(22,003)	(18,354)	(21,158)	(35,571)	(21,203)

Comprehensive Income ($ in thousands)
Annual | Quarterly

	12/31/2025 Q4	9/30/2025 Q3	6/30/2025 Q2	3/31/2025 Q1	12/31/2024 Q4	9/30/2024 Q3
Net loss:	(18,106)	(22,003)	(18,354)	(21,158)	(35,571)	(21,203)
Other comprehensive income (loss)	(16)	74	(54)	(121)	(181)	453
Comprehensive loss, net of tax, attributable to parent:	(18,122)	(21,929)	(18,408)	(21,279)	(35,752)	(20,750)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Financial Reporting
and Analysis Software

Pyxis Oncology, Inc. (PYXS) Financial Statements (2026 and earlier)

Company Profile

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

Comprehensive Income ($ in thousands)
Annual | Quarterly

Statements Sources

Login to ReadyRatios

Financial Reportingand Analysis Software

Pyxis Oncology, Inc. (PYXS) Financial Statements (2026 and earlier)

Company Profile

Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly

Income Statement (P&L) ($ in thousands)Annual | Quarterly

Comprehensive Income ($ in thousands)Annual | Quarterly

Statements Sources

Login to ReadyRatios

Financial Reporting
and Analysis Software

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

Comprehensive Income ($ in thousands)
Annual | Quarterly